Dr. Saiama N. Waqar
Claim this profileWashington University School of Medicine
About Saiama N. Waqar
Education:
- Obtained MBBS from Aga Khan University Hospital, Karachi, Pakistan (1996-2001).
- Earned MSCI from Washington University School of Medicine, St. Louis, MO.
Experience:
- Currently serves as Professor of Medicine and Director of Education for Oncology at Washington University School of Medicine, St. Louis, MO.
- Held the position of Associate Professor of Medicine and Research Director for Thoracic Oncology at the same institution.
- Actively involved in interviewing for residency and fellowship programs at Washington University since 2013.
- Engaged in various committees and grants at Washington University and Siteman Cancer Center since 2011.
Area of expertise
Lung Cancer
Saiama N. Waqar has run 18 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Saiama N. Waqar has run 13 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Washington University School Of Medicine
Siteman Cancer Center At West County Hospital
Clinical Trials Saiama N. Waqar is currently running
NVL-655
for NSCLC
This trial is testing a new drug called NVL-655 to see if it is safe and effective for patients with advanced ALK-positive lung cancer and other solid tumors. The drug works by blocking a protein that helps cancer cells grow. The study focuses on patients who have specific genetic changes and may not respond well to standard treatments. Newer treatments have been shown to improve outcomes in ALK-translocated lung cancer compared to older treatments.
Recruiting
1 award
Phase 1 & 2
7 criteria
Tepotinib + Ramucirumab
for Lung Cancer
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.
Recruiting
1 award
Phase 2
4 criteria
More about Saiama N. Waqar
Clinical Trial Related
4 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 6 Active Clinical Trials
Treatments Saiama N. Waqar has experience with
- Durvalumab
- Atezolizumab
- Ramucirumab
- Pembrolizumab
- Docetaxel
- AL8326
Breakdown of trials Saiama N. Waqar has run
Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Saiama N. Waqar specialize in?
Saiama N. Waqar focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Saiama N. Waqar currently recruiting for clinical trials?
Yes, Saiama N. Waqar is currently recruiting for 5 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Saiama N. Waqar has studied deeply?
Yes, Saiama N. Waqar has studied treatments such as Durvalumab, Atezolizumab, Ramucirumab.
What is the best way to schedule an appointment with Saiama N. Waqar?
Apply for one of the trials that Saiama N. Waqar is conducting.
What is the office address of Saiama N. Waqar?
The office of Saiama N. Waqar is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.